Approximately 57% of patients experienced decrease in appetite, which was consistent across the PIONEER trials [35,36,37,38,39,40,41,42,43,44]
After treatment with exenatide or liraglutide, six of seven patients enrolled in the study saw either an improvement or lack of change in PASI
Its effects on insulin release, glucagon, and stomach emptying make its glucose-lowering action more predictable in clinical use
Depending on your situation, other medications may be appropriate: Tirzepatide (brand name Mounjaro or Zepbound) is a dual GLP-1/GIP receptor agonist that has shown even greater weight loss in clinical trials
A 2024 FDA inspection of their outsourcing facility found that they released a batch of pyridoxine HCL (vitamin B6) despite microbial contamination being detected in the room where it was manufactured
This combination of effects on appetite, digestion, and blood sugar helps create a calorie deficit that leads to weight loss over time